US EditionPublished • loading... • Updated
Io Therapeutics Presents Today at the American Society for Hematology Annual Meeting, Preclinical Studies Demonstrating Combination Treatment with BCMA CAR-T Cells Plus the Company's RXR Agonist Compound IRX4204 Has Synergistic Efficacy Against Human Mult
IRX4204 enhances BCMA CAR-T cell persistence and lenalidomide efficacy by modulating ferroptosis, supporting planned clinical trials for multiple myeloma, researchers reported.
- Dec. 06, 2025, Io Therapeutics, Inc. and Duke University School of Medicine presented preclinical IRX4204 data at the 67th American Society of Hematology Annual Meeting in Orlando, Florida.
- IRX4204 suppressed CHAC1‑driven ferroptosis and activated mitophagy, protecting BCMA CAR‑T cells from exhaustion and ferroptotic death to enhance persistence and anti‑tumor function.
- In vivo, combination treatment with IRX4204 and lenalidomide significantly reduced tumor growth and prolonged median survival in multiple myeloma xenograft mouse models without increased systemic toxicity.
- The company plans clinical evaluations of IRX4204 with CAR‑T cells and lenalidomide in clinical trials in multiple myeloma patients, following its chronic‑dosing safety profile in phase I and II clinical trials.
- The data identify a druggable ferroptosis pathway and provide a rationale for combining RXR agonists with BCMA CAR‑T cells and lenalidomide, while IRX4204's potency positions it for broader clinical utility.
Insights by Ground AI
11 Articles
11 Articles
Globe Newswire+9 Reposted by 9 other sources
Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company's RXR agonist compound IRX4204 has synergistic efficacy against human mult
Io Therapeutics announced at the American Society of Hematology studies of their RXR agonist IRX4204 in combination with CAR-T cells for multiple myeloma...
K36 Therapeutics announces presentation of First-in-Human Clinical Data for Gintemetostat (KTX-1001) Demonstrating Target Engagement and Clinical Activity in Multiple Myeloma at ASH 2025 and the Appointment of Dr. Shinta Cheng, M.D., Ph.D., as Chief Medic
First-in-human data highlights safety, pharmacodynamics, and single-agent activity supporting MMSET/NSD2 inhibition in heavily pre-treated multiple myeloma patients
·United States
Read Full ArticleCoverage Details
Total News Sources11
Leaning Left8Leaning Right1Center1Last UpdatedBias Distribution80% Left
Bias Distribution
- 80% of the sources lean Left
80% Left
L 80%
Factuality
To view factuality data please Upgrade to Premium
